Skip to content

Exploring a Novel Immunosuppressive Pathway in Sepsis and Its Therapeutic Potential

LAG3/FGL1 Axis-Mediated CD8? T Cell Exhaustion in Sepsis-Induced Immunosuppression: Mechanisms and Targeted Intervention Research

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117946
Enrollment
Unknown
Registered
2026-01-30
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Healthy control group:None

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.All patients should be aged 18–70 years; 2.Meet the diagnostic criteria for sepsis, with a Sepsis-related Organ Failure Assessment (SOFA) score of 2 or higher, and have a clearly identified source of infection; 3.First-time diagnosis of sepsis, with no prior immunosuppressive therapy; 4.All patients or their family members should have provided signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with severe immunodeficiency diseases, such as HIV infection or advanced malignant tumors; 2.Pregnant or lactating women; 3.Having received immunomodulatory therapy, such as anti-PD-1 antibody, within 72 hours prior to enrollment; 4.Severe hepatic or renal insufficiency (e.g., baseline creatinine >200 µmol/L or ALT >3 times the upper limit of normal [ULN]); 5.Life expectancy of less than 7 days (e.g., due to severe multiple organ failure).

Design outcomes

Primary

MeasureTime frame
Lymphocyte activation gene-3,CD8+ Tcell(LAG3+ CD8+ Tcell)?Fibrinogen-like protein 1(FGL1);

Countries

China

Contacts

Public ContactJuanjuan Li

Zhejiang Provincial People's Hospital

lijuanjuan-1@163.com+86 571 87312778

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026